ecteinascidin 743 has been researched along with Solitary Fibrous Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blay, JY; Bompas, E; Bui-Nguyen, B; Chaigneau, L; Chaltiel, L; Chevreau, C; Cousin, P; Delord, JP; Khalifa, J; Le Cesne, A; Le Guellec, S; Ouali, M; Penel, N; Piperno-Neumann, S; Rios, M | 1 |
| Badalamenti, G; Bello, E; Casali, PG; Collini, P; Colombo, C; Cominetti, D; D'Incalci, M; Dagrada, GP; Dei Tos, AP; Frapolli, R; Gronchi, A; Morosi, C; Negri, T; Pilotti, S; Provenzano, S; Renne, SL; Saponara, M; Stacchiotti, S; Tortoreto, M; Vincenzi, B; Zaffaroni, N; Zuco, V | 1 |
2 other study(ies) available for ecteinascidin 743 and Solitary Fibrous Tumors
| Article | Year |
|---|---|
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
Topics: Adult; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sarcoma; Solitary Fibrous Tumors; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar Neoplasms; Dacarbazine; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Furans; Humans; Ifosfamide; Ketones; Kidney Neoplasms; Male; Meningeal Neoplasms; Mice, SCID; Middle Aged; Pleural Neoplasms; Response Evaluation Criteria in Solid Tumors; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Solitary Fibrous Tumors; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |